Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (GEMDOC-MMC)
A Prospective, Randomized, Open-Label, Phase II Trial Comparing Sequential Intravesical Gemcitabine Plus Docetaxel With Sequential Intravesical Gemcitabine Plus Mitomycin C in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
調査の概要
詳細な説明
High-grade BCG-unresponsive non-muscle-invasive bladder cancer remains a major therapeutic challenge. Radical cystectomy is considered the standard treatment; however, many patients are unwilling or medically unfit to undergo surgery. Sequential intravesical chemotherapy has emerged as a bladder-preserving treatment strategy with encouraging oncological outcomes.
This prospective, randomized, open-label, single-center phase II trial is designed to compare the efficacy and safety of two sequential intravesical chemotherapy regimens following complete TURBT.
Eligible patients with histologically confirmed BCG-unresponsive high-grade NMIBC will be randomized in a 1:1 ratio to receive either sequential intravesical gemcitabine followed by docetaxel or sequential intravesical gemcitabine followed by mitomycin C.
Both treatment regimens consist of a six-week induction course followed by monthly maintenance instillations for twelve months according to the study protocol. Clinical follow-up includes cystoscopy, urine cytology, pelvic ultrasonography, adverse event assessment according to CTCAE criteria, and quality-of-life evaluation using the EORTC QLQ-C30 and EORTC QLQ-NMIBC24 questionnaires.
The primary endpoint is 12-month event-free survival. Secondary endpoints include cystectomy-free survival, progression-free survival, safety, tolerability, and comparative efficacy of both treatment strategies.
A total of 228 participants will be enrolled. Statistical analyses will be performed according to the intention-to-treat principle using Kaplan-Meier survival analysis, log-rank testing, and Cox proportional hazards regression.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Nshan Sedrakyan, MD
- 電話番号:+79165663100
- メール:nick977773@gmail.com
研究場所
-
-
Moscow
-
Moscow、Moscow、ロシア、115522
- 募集
- N.N. Blokhin National Medical Research Center of Oncology
-
コンタクト:
- Nshan Sedrakyan, MD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed BCG-unresponsive non-muscle-invasive urothelial bladder cancer (NMIBC).
- Complete transurethral resection of bladder tumor (TURBT) before study treatment.
- Intermediate- or high-risk NMIBC according to current clinical guidelines.
- Candidate for intravesical chemotherapy.
- ECOG performance status 0-2.
- Adequate hematologic, renal, and hepatic function.
- Written informed consent.
Exclusion Criteria:
- Muscle-invasive (≥T2), locally advanced, or metastatic urothelial carcinoma.
- Upper urinary tract urothelial carcinoma requiring treatment.
- Previous hypersensitivity to gemcitabine, docetaxel, mitomycin C, or formulation components.
- Active uncontrolled urinary tract infection.
- Pregnancy or breastfeeding.
- Concurrent participation in another interventional clinical trial.
- Any serious uncontrolled medical condition that, in the investigator's opinion, would interfere with study participation or interpretation of results.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Sequential Gemcitabine + Docetaxel
Participants receive sequential intravesical gemcitabine followed by docetaxel after complete TURBT.
Treatment consists of six weekly induction instillations followed by monthly maintenance instillations for 12 months.
|
Intravesical gemcitabine 1 g dissolved in 50 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 minutes before drainage.
Intravesical docetaxel 37.5 mg dissolved in 50 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 to 120 minutes following gemcitabine administration.
他の名前:
|
|
アクティブコンパレータ:Sequential Gemcitabine + Mitomycin C
Participants receive sequential intravesical gemcitabine followed by mitomycin C after complete TURBT.
Treatment consists of six weekly induction instillations followed by monthly maintenance instillations for 12 months.
|
Intravesical gemcitabine 1 g dissolved in 50 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 minutes before drainage.
Intravesical mitomycin C 40 mg dissolved in 40 mL of 0.9% sodium chloride.
The solution is retained in the bladder for 90 minutes following gemcitabine administration.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
12-Month Event-Free Survival
時間枠:12 months after randomization
|
Event-free survival is defined as the time from randomization to the first occurrence of histologically confirmed recurrence, disease progression to muscle-invasive bladder cancer, radical cystectomy, distant metastasis, or death from any cause.
|
12 months after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival
時間枠:Up to 12 months
|
Time from randomization to progression to muscle-invasive or metastatic urothelial carcinoma.
|
Up to 12 months
|
|
Cystectomy-Free Survival
時間枠:Up to 12 months
|
Time from randomization to radical cystectomy for bladder cancer.
|
Up to 12 months
|
|
Treatment-Related Adverse Events
時間枠:Throughout study treatment and follow-up
|
Incidence and severity of adverse events graded according to CTCAE.
|
Throughout study treatment and follow-up
|
|
Health-Related Quality of Life (EORTC QLQ-C30)
時間枠:Baseline through 12 months
|
Change from baseline in EORTC QLQ-C30 scores.
|
Baseline through 12 months
|
|
Health-Related Quality of Life (EORTC QLQ-NMIBC24)
時間枠:Baseline through 12 months
|
Change from baseline in EORTC QLQ-NMIBC24 scores.
|
Baseline through 12 months
|
協力者と研究者
捜査官
- 主任研究者:Vsevolod Matveev, MD, PhD、N.N. Blokhin National Medical Research Center of Oncology
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NMIBC-GEMDOC-001
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。